Pfizer Inc.

PFE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Sep 2025 Jun 2025 Mar 2025 Sep 2024 Jun 2024 Mar 2024
Operating Activities
Net Income $-248.0M $2.69B $3.54B $2.91B $2.97B $4.47B $41.0M $3.12B
Depreciation & Amortization $1.62B $1.61B $1.66B $1.63B $1.62B $1.76B $1.73B $1.74B
Depreciation
Amortization $1.20B $1.30B
Stock-Based Compensation $272.0M $170.0M $220.0M
Net Cash from Operating Activities $835.0M $2.62B $4.60B $-582.0M $2.34B $6.71B $-1.78B $1.09B
Investing Activities
Capital Expenditures $533.0M $436.0M $602.0M $618.0M $564.0M $651.0M $637.0M $704.0M
Business Acquisitions
Net Cash from Investing Activities $785.0M $3.27B $1.73B
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-2.86B $-5.23B $-4.93B
Net Change in Cash $563.0M $375.0M $-2.14B
Free Cash Flow $302.0M $2.18B $4.00B $-1.20B $1.77B $6.06B $-2.42B $386.0M
← Newer Page 1 of 7 Older →